2011•PubMedOpen access

[Modified Restriction Enzyme-based Detection of EGFR Mutations in Lung Cancer].

Fan Yang, Kezhong Chen, Guanchao Jiang, Jianfeng Li, Jun Wang

Open full text 0 citations

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutation in lung cancer is a reliable predictor of the efficacy of tyrosine kinase inhibitors, so detection of gene mutation has very important clinical significance. The aim of this study is to optimize conditions for restriction enzyme-based mutant enriched detection of EGFR mutation in lung cancer specimens. METHODS: EGFR somatic mutations identified in DNA specimens from 251 lung adenocarcinomas with modified mutant enriched method and direct sequencing were compared. The sensitivity of the modified method was determined by serial dilution of mutant-carrying lung cancer cells in wild-type cells. RESULTS: 46 deletion mutations in exon 19 and 26 point mutations in exon 21 were found by sequencing, while modified method identified another 78 deletions in exon 19 and 57 substitutions in exon 21 with a mutation rate of 53.8%. Sensitivity of this modified method was 0.5% (mutant/wild type) in serial diluted cells. CONCLUSIONS: The modified restriction enzyme-based method is convenient for clinical EGFR mutation screening in non-small cell lung cancer for its simpleness, cost-saving and high sensitivity.

About this research paper

What this paper is about

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutation in lung cancer is a reliable predictor of the efficacy of tyrosine kinase inhibitors, so detection of gene mutation has very important clinical significance. The aim of this study is to optimize conditions for restriction enzyme-based mutant enriched detection of EGFR mutation in lung cancer specimens. METHODS: EGFR somatic mutations identified in DNA specimens from 251 lung adenocarcinomas with modified mutant enriched method and direct sequencing were compared. The sensitivity of the modified method was determined by serial dilution of mutant-carrying lung cancer cells in wild-type cells. RESULTS: 46 deletion mutations in exon 19 and 26 point mutations in exon 21 were found by sequencing, while modified method identified another 78 deletions in exon 19 and 57 substitutions in exon 21 with a mutation rate of 53.8%. Sensitivity of this modified method was 0.5% (mutant/wild type) in serial diluted cells. CONCLUSIONS: The modified restriction enzyme-based method is convenient for clinical EGFR mutation screening in non-small cell lung cancer for its simpleness, cost-saving and high sensitivity.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutation in lung cancer is a reliable predictor of the efficacy of tyrosine kinase inhibitors, so detection of gene mutation has very important clinical significance. The aim of this study is to optimize conditions for restriction enzyme-based mutant enriched detection of EGFR mutation in lung cancer specimens. METHODS: EGFR somatic mutations identified in DNA specimens from 251 lung adenocarcinomas with modified mutant enriched method and direct sequencing were compared. The sensitivity of the modified method was determined by serial dilution of mutant-carrying lung cancer cells in wild-type cells. RESULTS: 46 deletion mutations in exon 19 and 26 point mutations in exon 21 were found by sequencing, while modified method identified another 78 deletions in exon 19 and 57 substitutions in exon 21 with a mutation rate of 53.8%. Sensitivity of this modified method was 0.5% (mutant/wild type) in serial diluted cells. CONCLUSIONS: The modified restriction enzyme-based method is convenient for clinical EGFR mutation screening in non-small cell lung cancer for its simpleness, cost-saving and high sensitivity.

Key concepts: Lung cancer, Exon, Mutant, Epidermal growth factor receptor, Point mutation, Mutation, Restriction enzyme, Molecular biology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Modified Restriction Enzyme-based Detection of EGFR Mutations in Lung Cancer]. — Research Paper | ScholarLens